Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
McKesson
Medtronic
Express Scripts
Colorcon
Cipla
Fuji
Chinese Patent Office
Dow

Generated: September 23, 2018

DrugPatentWatch Database Preview

Fougera Company Profile

« Back to Dashboard

What is the competitive landscape for FOUGERA, and when can generic versions of FOUGERA drugs launch?

FOUGERA has one hundred and nineteen approved drugs.

There are four US patents protecting FOUGERA drugs.

Summary for Fougera
US Patents:4
Tradenames:56
Ingredients:48
NDAs:119
Patent Litigation for Fougera: See patent lawsuits for Fougera

Drugs and US Patents for Fougera

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms DIFLORASONE DIACETATE diflorasone diacetate CREAM;TOPICAL 075187-001 Mar 30, 1998 DISCN No No ➤ Sign Up ➤ Sign Up
Fougera Pharms CICLOPIROX ciclopirox SHAMPOO;TOPICAL 090146-001 May 25, 2010 AT RX No No ➤ Sign Up ➤ Sign Up
Fougera Pharms TRIAMCINOLONE ACETONIDE triamcinolone acetonide LOTION;TOPICAL 040467-002 Apr 21, 2003 AT RX No No ➤ Sign Up ➤ Sign Up
Fougera Pharms Inc FLUOCINONIDE fluocinonide CREAM;TOPICAL 073030-001 Oct 17, 1994 AB1 RX No No ➤ Sign Up ➤ Sign Up
Fougera Pharms Inc HYDROCORTISONE hydrocortisone CREAM;TOPICAL 080693-003 Approved Prior to Jan 1, 1982 AT RX No Yes ➤ Sign Up ➤ Sign Up
Fougera Pharms PAMINE methscopolamine bromide TABLET;ORAL 008848-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Fougera Pharms DESOXIMETASONE desoximetasone CREAM;TOPICAL 078369-001 Jun 29, 2010 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Fougera

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fougera Pharms ACLOVATE alclometasone dipropionate OINTMENT;TOPICAL 018702-001 Dec 14, 1982 4,124,707 ➤ Sign Up
Fougera Pharms CUTIVATE fluticasone propionate OINTMENT;TOPICAL 019957-001 Dec 14, 1990 4,335,121*PED ➤ Sign Up
Fougera Pharms ACLOVATE alclometasone dipropionate CREAM;TOPICAL 018707-001 Dec 14, 1982 4,124,707 ➤ Sign Up
Fougera Pharms SOLARAZE diclofenac sodium GEL;TOPICAL 021005-001 Oct 16, 2000 5,639,738 ➤ Sign Up
Fougera Pharms TEMOVATE clobetasol propionate CREAM;TOPICAL 019322-001 Dec 27, 1985 3,721,687 ➤ Sign Up
Fougera Pharms TEMOVATE clobetasol propionate OINTMENT;TOPICAL 019323-001 Dec 27, 1985 3,721,687 ➤ Sign Up
Fougera Pharms PANDEL hydrocortisone probutate CREAM;TOPICAL 020453-001 Feb 28, 1997 4,794,106 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for FOUGERA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Lotion 0.05% ➤ Subscribe 2008-07-28
➤ Subscribe Topical Gel 3% ➤ Subscribe 2009-12-16

Supplementary Protection Certificates for Fougera Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
401 Luxembourg ➤ Sign Up PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
00617 Netherlands ➤ Sign Up PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
C0002 Belgium ➤ Sign Up PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
C/GB99/043 United Kingdom ➤ Sign Up PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
00581 Netherlands ➤ Sign Up PRODUCT NAME: DROOG EXTRACT VAN GROENE THEE; NAT. REGISTRATION NO/DATE: RVG 110904 20120917; FIRST REGISTRATION: 73486.00.00 20090831
2012 00040 Denmark ➤ Sign Up
0550 Netherlands ➤ Sign Up PRODUCT NAME: DROOG EXTRACT VAN GROENE THEE (CAMELLIA SINENSIS (L.) O.KUNZE FOLIUM) WATERIG (24-56:1) WAARVAN 100 MG OVEREENKOMT MET : 55-72 MG VAN (-)- EPIGALLOCATECHINEGALLAAT. EERSTE EXTRACTIEMIDDEL: WATER; NATIONAL REGISTRATION NO/DATE: RVG 110904 20120920; FIRST REGISTRATION: DE 73486.00.00 20090831
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
US Department of Justice
Mallinckrodt
Express Scripts
QuintilesIMS
Fish and Richardson
Cipla
Farmers Insurance
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.